R&D Insights: How Lantheus Holdings, Inc. and Amicus Therapeutics, Inc. Allocate Funds

Biotech R&D: Amicus vs. Lantheus Spending Strategies

__timestampAmicus Therapeutics, Inc.Lantheus Holdings, Inc.
Wednesday, January 1, 20144762400013673000
Thursday, January 1, 20157694300014358000
Friday, January 1, 201610479300012203000
Sunday, January 1, 201714931000018125000
Monday, January 1, 201827090200017071000
Tuesday, January 1, 201928637800020018000
Wednesday, January 1, 202030844300032788000
Friday, January 1, 202127204900044966000
Saturday, January 1, 2022276677000311681000
Sunday, January 1, 202315238100077707000
Loading chart...

Igniting the spark of knowledge

R&D Spending: A Tale of Two Biotech Innovators

In the dynamic world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Amicus Therapeutics, Inc. and Lantheus Holdings, Inc. have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Amicus Therapeutics consistently allocated a significant portion of its resources to R&D, peaking in 2020 with a 548% increase from 2014 levels. In contrast, Lantheus Holdings showed a more conservative growth, with a notable surge in 2022, marking a 2,179% increase from its 2014 spending. This divergence highlights Amicus's aggressive pursuit of new therapies, while Lantheus's strategy appears more measured, focusing on sustainable growth. As the biotech landscape evolves, these spending patterns offer valuable insights into each company's strategic priorities and potential future breakthroughs.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025